Stock Update On Nwtt, Pfe And Mar From Pennytobuck.com
NW Tech Capital Inc., (PINK SHEETS:NWTT) recently reported that the company is currently
working on raising the company value back for its shareholders and seeks viable candidates to merge into NWTT. The company management has been seeking viable businesses to vend in in North America, Asia, and Europe. NWTT is determined to reenter the public markets as a viable and respectable business.
NWTT also recently reported that the company had finalized the merger with Bermal Contracting Ltd., a BC Canada company.
NWTT management currently works on raising the company value back for its shareholders and seeks viable candidates to merge into NWTT. NWTTs management has been seeking viable businesses to vend in, in North America, Asia and Europe. NWTT is determined to reenter the public markets as a viable and respectable business.
To receive additional information about NWTT, please visit the website at http://www.nwtechcapital.com
Pfizer Inc. (NYSE:PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, recently announced that they have entered into an agreement under which PFE will acquire FoldRx.
FoldRxs portfolio includes clinical and pre-clinical programs for investigational compounds to treat diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases. FoldRxs lead product candidate, tafamidis meglumine, is in registration as an oral, disease-modifying therapy for TTR amyloid polyneuropathy , a progressively fatal genetic neurodegenerative disease, for which liver transplant is the only treatment option that is currently available.
About Transthyretin Amyloidosis (ATTR-PN)
Transthyretin (TTR) is an amyloidogenic protein secreted by the liver. Mutations in the TTR gene have been linked to several amyloid conditions. Deposition of TTR amyloid in the peripheral nerve tissue results in transthyretin amyloid polyneuropathy (ATTR-PN), a sensory, motor and autonomic polyneuropathy. The disease usually begins in the third or fourth decade with symptoms of peripheral and/or autonomic neuropathy that inexorably progress to involve muscle strength with loss of ambulation. The patient commonly experiences a profoundly diminished quality of life with a markedly reduced life expectancy (approximately 10 years from first symptom). Liver transplantation is the only accepted treatment, but it is not uniformly effective, and is associated with significant mortality. It is estimated that ATTR-PN affects at least 8,000 patients worldwide, the majority of whom are in the European Union.
About FoldRx
FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute). Protein misfolding is increasingly being recognized as an underlying cause of many chronic degenerative diseases. By applying FoldRxs proprietary expertise in protein folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRxs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinsons, and Huntingtons disease based on its broad, proprietary, yeast-based drug discovery platform. FoldRx investors include Alta Partners, Fidelity Biosciences, Healthcare Ventures, Morgenthaler Ventures, Novartis Venture Funds, Novo Ventures, and TPG Biotechnology. For more information on FoldRx, please visit the companys web site at www.foldrx.com.
Marriott International, Inc. (NYSE:MAR) is a leading lodging company with more than 3,400 lodging properties in 70 countries and territories.
Marriott International operates and franchises hotels under the Marriott, JW Marriott, The Ritz-Carlton, The Autograph Collection, Renaissance, Residence Inn, Courtyard, TownePlace Suites, Fairfield Inn, SpringHill Suites and Bulgari brand names; develops and operates vacation ownership resorts under the Marriott Vacation Club, The Ritz-Carlton Destination Club, and Grand Residences by Marriott brands; licenses and manages whole-ownership residential brands, including The Ritz-Carlton Residences, JW Marriott Residences and Marriott Residences; operates Marriott Executive Apartments; provides furnished corporate housing through its Marriott ExecuStay division; and operates conference centers.
Marriott International Reported Second Quarter 2010 Results
The Company MAR second quarter 2010 net income totaled $119 million, a 42 percent increase compared to second quarter 2009 adjusted net income.
Diluted EPS totaled $0.31, a 35 percent increase from adjusted diluted EPS in the year-ago quarter.
On April 22, 2010, the company forecasted second quarter diluted EPS of $0.25 to $0.29.
For more information about this company please visit http://www.marriott.com
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (PenStox) for (15) days of advertising for NW Tech Capital, Inc. (NWTT.PK).
by: Bill Pennyman
Recognizing Great Talent And Potential Pennytobuck Stock Updates On Nuec, Sigm And Cpwr The Real "Shock and Awe" Mslp, Orex, Mpel On Pennytobuck Stock Updates Stock Update On Crwe, Rnin And Eqlb From Pennytobuck.com Orfg, Eqlb And Mmr On Pennytobucks Stock Highlights For September 7th, 2010. Stocks On The Pennytobuck Highlight Include Eqlb, Kore And Uwn Climb For A Cause's "Peak Performers" Smash All Previous Fundraising Records 7 Signs That Someone Is Attracted To You And That They Like You The Pros And Cons Of Argireline Boston Fans and Players Alike Enjoy HD Maximum Earnings And How To Avoid ' Smart Pricing ' Beekeeping and Understanding the Bee Hive